Molecular radiotheranostics for neuroendocrine tumours

Area of Science:

• Nuclear Medicine
• Oncology
• Radiotherapy

Background:

• Neuroendocrine tumours (NETs) require precise management strategies.
• Conventional imaging may not fully capture NET characteristics.
• Nuclear medicine offers advanced diagnostic and therapeutic options.

Purpose of the Study:

• To highlight the critical role of nuclear medicine in managing neuroendocrine tumours (NETs).
• To emphasize the impact of somatostatin receptor scintigraphy compared to conventional imaging.
• To explain the patient selection process for molecular radiotherapy in NETs.

Main Methods:

• Utilizing somatostatin receptor scintigraphy for NET diagnosis and management.
• Employing molecular radiotherapy as a therapeutic approach for NETs.
• Correlating radionuclide imaging uptake with therapeutic agent concentration in tumours.

Main Results:

• Somatostatin receptor scintigraphy demonstrates a high impact on patient management.
• Molecular radiotherapy is an integral component of NET treatment.
• Radionuclide imaging effectively preselects patients likely to benefit from radiotherapy.

Conclusions:

• Nuclear medicine imaging and therapy are essential for effective NET management.
• Somatostatin receptor scintigraphy plays a pivotal role in guiding treatment decisions.
• Molecular radiotherapy, guided by imaging, offers targeted treatment for NET patients.